<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519270</url>
  </required_header>
  <id_info>
    <org_study_id>IGN002-101</org_study_id>
    <nct_id>NCT02519270</nct_id>
  </id_info>
  <brief_title>Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects</brief_title>
  <acronym>NHL</acronym>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and&#xD;
      Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with&#xD;
      Refractory Non-Hodgkin Lymphoma (NHL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, non-randomized, first-in-human Phase 1 study involves two stages:&#xD;
&#xD;
      In the Dose-Escalation Stage, ascending dose cohorts will be treated in 2 periods until the&#xD;
      maximum tolerated dose is identified. In Period 1, subjects will receive 2 doses of IGN002&#xD;
      administered weekly. In Period 2, subjects will receive up to 24 additional doses of IGN002&#xD;
      administered weekly in three 8-week cycles. Subjects that have not progressed following the&#xD;
      treatment period will be followed for another 6 months.&#xD;
&#xD;
      In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the identified&#xD;
      maximum tolerated dose administered weekly in three 8-week cycles. Subjects that have not&#xD;
      progressed following the treatment period will be followed for another 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of multiple doses of IGN002 administered weekly as an intravenous (IV) infusion to subjects with refractory NHL</measure>
    <time_frame>Weekly for 6 months</time_frame>
    <description>Adverse Event collection and assessment will be done for all potentially treated subjects to assess the safety, tolerability, and determine the maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of ascending doses of IGN002 administered weekly</measure>
    <time_frame>Weekly for 6 months</time_frame>
    <description>Pharmacokinetic (PK) parameters such as Maximum concentration (Cmax), time to maximum concentration (Tmax), minimum concentration(Cmin), area under the curve (AUC), half-life (t1/2), clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the anti-tumor activity of IGN002 using the Lugano Classification for NHL</measure>
    <time_frame>Every 8 weeks for 6 months, then at 1, 3 and 6 months</time_frame>
    <description>Determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in NHL patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Stage/ Expansion Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.&#xD;
In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGN002</intervention_name>
    <description>IGN002 is a monoclonal antibody fusion protein.</description>
    <arm_group_label>Dose Escalation Stage/ Expansion Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented history of immunohistochemistry (IHC)-confirmed CD20-positive (with no&#xD;
             subsequent history of CD20-negativity) B-cell, NHL, including diffuse large B cell&#xD;
             (DLBCL), mantle cell, marginal zone, lymphoplasmacytic, follicular, transformed&#xD;
             follicular, or primary mediastinal B cell lymphoma&#xD;
&#xD;
          -  Refractory disease, having failed available therapies&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with an approved or investigational chemotherapy drug within 28 days of Day&#xD;
             1&#xD;
&#xD;
          -  Treatment with an approved or investigational anti-CD20 drug within 28 days of Day 1&#xD;
&#xD;
          -  Treatment with an approved or investigational biologic drug that does not target CD20&#xD;
             within 90 days of Day 1&#xD;
&#xD;
          -  Radiation therapy within 4 weeks of Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tamika Nelson-Glass</last_name>
    <email>ign002-101study@sppirx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

